Chlorosuccinimide → (R)-tert-Butoxycarbonylamino-[4-(2-methoxy-ethoxy)-phenyl]-acetic acid

HRID 561989

反応式

HRID 561989 の反応式
IC1C=CC(C2NC([C@@H](N3C(=O)[C@@H](CCC(O)=O)NC3=O)C(C)C)=NC=2)=CC=1.C(OC(=O)N[C@H](C1NC(C2C=CC=CC=2F)=CN=1)[C@H](C1C=CC=CC=1)C)(C)(C)C.ClN1C(=O)CCC1=O.C(OC(N[C@H](C1C=CC(OCC(=O)N(C)C)=CC=1)C(O)=O)=O)(C)(C)C.[C:91]([O:95][C:96]([NH:98][C@H:99]([C:103]1[CH:108]=[CH:107][C:106]([O:109][CH2:110][CH2:111][O:112][C:113](C)(C)C)=[CH:105][CH:104]=1)[C:100]([OH:102])=[O:101])=[O:97])([CH3:94])([CH3:93])[CH3:92].BrCCOC>>[C:91]([O:95][C:96]([NH:98][C@H:99]([C:103]1[CH:104]=[CH:105][C:106]([O:109][CH2:110][CH2:111][O:112][CH3:113])=[CH:107][CH:108]=1)[C:100]([OH:102])=[O:101])=[O:97])([CH3:94])([CH3:93])[CH3:92]

参加物

7

実験手順

Prepared by the same method as described in example 1 except that (i) (2S)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid was used in place of (2S,3S)-2-tert-butoxycarbonylamino-3-phenyl-butyric acid in step 53-E; (ii) chlorination of the 5-position of the imidazole ring with N-chlorosuccinimide in step 53-F was omitted and (iii) (R)-tert-butoxycarbonylamino-[4-(2-methoxy-ethoxy)-phenyl]-acetic acid was in place of (R)-tert-butoxycarbonylamino-[4-(2-tert-butoxy-ethoxy)-phenyl]-acetic acid in step 53-G. (R)-tert-Butoxycarbonylamino-[4-(2-methoxy-ethoxy)-phenyl]-acetic acid was prepared as described in example 1 for the preparation of (R)-tert-butoxycarbonylamino-[4-(2-tert-butoxy-ethoxy)-phenyl]-acetic acid except that 1-bromo-2-methoxy-ethane was used in place of 2-(2-iodo-ethoxy)-2-methyl-propane. HR-MS: calcd for C29H26FlN4O4 [M+H+] 641.1056. Found 641.1053.

後処理

  1. customPrepared by the same method

出典と根拠

ORDレコード
ord-8130d420164a4c10ba512b26bc0c39c0
出典データセット
uspto-grants-2011_11
特許番号
US08063085B2

関連ノート

読み込み中…